Niche Pharmaceuticals launches microsite for migraine sufferers

SOUTHLAKE, Texas - Niche Pharmaceuticals on Wednesday launched a microsite (www.MagnesiumRoadtoMigrainePrevention.com) which features an overview of the research done on the link between magnesium deficiency and chronic migraine headaches. 

 

Niche Pharmaceuticals cites published clinical trials that have shown that daily magnesium supplementation taken for a minimum of two to three months can reduce the occurrence of migraine days by at least 50%. According to the company, the American Headache Society and the American Academy of Neurology now include oral magnesium in their preventive treatment guidelines for migraines. 

 

Mag-Tab SR is Niche's magnesium product that has a unique formulation that delivers magnesium L-lactate dihydrate into the body slowly for maximum absorption. Taken daily, Mag-Tab SR provides twenty-four hours of continuous magnesium supplementation. The slow release component leads to better uptake in the body's cells and relief of many symptoms associated with magnesium deficiency. 

 

Approximately four out of five people in the United States do not get enough magnesium in their diet and may be magnesium deficient, Niche Pharmaceuticals reported. And up to 50% of the 36 million American migraine sufferers have low magnesium levels associated with their chronic migraines, the company added.